{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:12:21Z","timestamp":1771326741467,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Antineutrophil cytoplasm antibody-associated vasculitis (AAV) with interstitial lung disease (AAV-ILD) is the main manifestation of AAV involving the lung, further increasing the risk of poor prognosis in patients with AAV. This study aimed to investigate the risk factors associated with mortality in patients with AAV-ILD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In Web of Science, PubMed, Embase and Scopus databases, a comprehensive search was performed for English studies on AAV and ILD published from inception date until May 17, 2024. Hazard ratios (HR) and 95% confidence intervals (CI) of mortality-related risk factors in AAV-ILD were collected, and subgroup analyses were carried out based on different candidate risk factors. Cochran's Q statistic and inconsistency value were utilized to assess the heterogeneity of included studies. Sensitivity analysis was executed using one-by-one\u00a0elimination method, and publication bias was evaluated with Egger's test and the trim-and-fill method.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 654 patients with AAV-ILD in eight studies were included for the pooled analysis of mortality risk factors. The results showed that age (HR\u2009=\u20091.06, 95%CI: 1.04, 1.08), ever smoker (HR\u2009=\u20091.61, 95%CI: 1.13, 2.29), usual interstitial pneumonia pattern (HR\u2009=\u20092.07, 95%CI: 1.43, 3.00), acute exacerbation (HR\u2009=\u20092.73, 95%CI: 1.70, 4.40) and microscopic polyangiitis (HR\u2009=\u20094.03, 95%CI: 1.70, 9.55) were associated with an increased risk of AAV-ILD mortality. Conversely, percent predicted forced vital capacity (HR\u2009=\u20090.97, 95%CI: 0.96, 0.99) and immunosuppressant for induction (HR\u2009=\u20090.40, 95%CI: 0.28, 0.58) were associated with a reduced risk of AAV-ILD mortality. Male (HR\u2009=\u20091.27, 95%CI: 0.90, 1.80), nervous system involvement (HR\u2009=\u20090.99, 95%CI: 0.65, 1.52), renal involvement (HR\u2009=\u20091.24, 95%CI: 0.97, 1.95) and five factor score\u2009\u2265\u20091 (HR\u2009=\u20091.00, 95%CI: 0.67, 1.48) showed no significant correlation with mortality risk in patients with AAV-ILD. Heterogeneity test indicated no significant heterogeneity among the pooled studies. The results of sensitivity analysis, Egger's test and the trim-and-fill method revealed that the pooled findings were stable and reliable.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The pooled analyses demonstrated that age, ever smoker, usual interstitial pneumonia pattern, acute exacerbation and microscopic polyangiitis were risk factors for mortality in patients with AAV-ILD, while percent predicted forced vital capacity and immunosuppressant therapy for induction serve as protective factors against mortality. A systematic understanding of the risk factors for AAV-ILD may provide clues for developing effective interventions and managements to improve poor prognosis in patients. \n<jats:table-wrap>\n                <jats:table>\n                  <jats:tbody>\n                    <jats:tr>\n                      <jats:td colspan=\"2\">\n                        <jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>Increase of age, ever smoker, usual interstitial pneumonia pattern, acute exacerbation and microscopic polyangiitis were risk factors for poor prognosis in patients with AAV-ILD.<\/jats:italic>\u2022 <jats:italic>High level of percent predicted forced vital capacity and immunosuppressant therapy for induction serve as protective factors against poor prognosis.<\/jats:italic>\u2022 <jats:italic>Male, nervous system involvement, renal involvement and five factor score \u2265 1 showed no significant correlation with poor prognosis in patients with AAV-ILD.<\/jats:italic>\n                      <\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody>\n                <\/jats:table>\n              <\/jats:table-wrap>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10067-025-07378-z","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T21:20:15Z","timestamp":1740604815000},"page":"1675-1689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk factors for poor prognosis in ANCA-associated vasculitis with interstitial lung disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Xing","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4085-5875","authenticated-orcid":false,"given":"Xixi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"7378_CR1","doi-asserted-by":"crossref","unstructured":"Vogt K, Fink CB, Schreibing TM et al (2024) Distinct pulmonary patterns in ANCA-associated vasculitides: insights from a retrospective single center cohort study[J]. Rheumatol Int","DOI":"10.1007\/s00296-024-05664-8"},{"key":"7378_CR2","doi-asserted-by":"publisher","first-page":"2499404","DOI":"10.1155\/2022\/2499404","volume":"2022","author":"JW Ha","year":"2022","unstructured":"Ha JW, Pyo JY, Ahn SS et al (2022) Incidence and Patterns of Interstitial Lung Disease and Their Clinical Impact on Mortality in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Korean Single-Centre Observational Study[J]. J Immunol Res 2022:2499404","journal-title":"J Immunol Res"},{"key":"7378_CR3","unstructured":"Sebastiani M, Manfredi A, Vacchi C et al (2020) Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis[J]. Clin Exp Rheumatol 38 Suppl 124(2):221\u2013231"},{"issue":"4","key":"7378_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000529085","volume":"102","author":"P Zhou","year":"2023","unstructured":"Zhou P, Li Z, Gao L et al (2023) Patterns of Interstitial Lung Disease and Prognosis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis[J]. Respiration 102(4):257\u2013273","journal-title":"Respiration"},{"issue":"2","key":"7378_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/rheumatology\/keac339","volume":"62","author":"B Doliner","year":"2023","unstructured":"Doliner B, Rodriguez K, Montesi SB et al (2023) Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality[J]. Rheumatology (Oxford) 62(2):716\u2013725","journal-title":"Rheumatology (Oxford)"},{"key":"7378_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102338","volume":"106","author":"T Maillet","year":"2020","unstructured":"Maillet T, Goletto T, Beltramo G et al (2020) Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor[J]. J Autoimmun 106:102338","journal-title":"J Autoimmun"},{"issue":"1","key":"7378_CR7","doi-asserted-by":"publisher","first-page":"2204449","DOI":"10.1080\/07853890.2023.2204449","volume":"55","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Ding Q, Lv C et al (2023) Clinical significance of microscopic polyangiitis with interstitial lung disease and bronchiectasis: probability of preexisting comorbidities[J]. Ann Med 55(1):2204449","journal-title":"Ann Med"},{"issue":"1","key":"7378_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides[J]. Arthritis Rheum 65(1):1\u201311","journal-title":"Arthritis Rheum"},{"issue":"6","key":"7378_CR9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM et al (2013) An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. Am J Respir Crit Care Med 188(6):733\u2013748","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"7378_CR10","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline[J]. Am J Respir Crit Care Med 198(5):e44-e68","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"7378_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol 25(9):603\u2013605","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"7378_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00408-022-00532-3","volume":"200","author":"S Yang","year":"2022","unstructured":"Yang S, Zhan X, Wang J et al (2022) Serum Oncomarkers in Patients with MPO-ANCA-Positive Vasculitis: Diagnostic and Prognostic Predictive Values for Interstitial Lung Disease[J]. Lung 200(3):331\u2013338","journal-title":"Lung"},{"key":"7378_CR13","doi-asserted-by":"publisher","first-page":"1064307","DOI":"10.3389\/fphar.2023.1064307","volume":"14","author":"MJ Kim","year":"2023","unstructured":"Kim MJ, Lee D, Choe J et al (2023) Long-term clinical course and outcomes of patients with microscopic polyangiitis-associated interstitial lung disease[J]. Front Pharmacol 14:1064307","journal-title":"Front Pharmacol"},{"issue":"6","key":"7378_CR14","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/j.chest.2021.01.083","volume":"159","author":"H Hozumi","year":"2021","unstructured":"Hozumi H, Kono M, Hasegawa H et al (2021) Clinical Significance of Interstitial Lung Disease and Its Acute Exacerbation in Microscopic Polyangiitis[J]. Chest 159(6):2334\u20132345","journal-title":"Chest"},{"issue":"1","key":"7378_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12890-021-01451-4","volume":"21","author":"X Sun","year":"2021","unstructured":"Sun X, Peng M, Zhang T et al (2021) Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody[J]. BMC Pulm Med 21(1):88","journal-title":"BMC Pulm Med"},{"issue":"1","key":"7378_CR16","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/s41598-021-81311-7","volume":"11","author":"S Matsuda","year":"2021","unstructured":"Matsuda S, Kotani T, Suzuka T et al (2021) Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease[J]. Sci Rep 11(1):1490","journal-title":"Sci Rep"},{"issue":"3","key":"7378_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/1756-185X.14532","volume":"26","author":"Y Takakuwa","year":"2023","unstructured":"Takakuwa Y, Yamasaki Y, Matsushita H et al (2023) Long-term survival, causes of death, and prognostic factors for mortality in patients with microscopic polyangiitis and those with anti-neutrophil cytoplasmic antibody-positive interstitial lung disease: A single-center retrospective study[J]. Int J Rheum Dis 26(3):446\u2013453","journal-title":"Int J Rheum Dis"},{"key":"7378_CR18","doi-asserted-by":"crossref","unstructured":"Patel A, Masiak A, Joshi S et al (2023) Influence of smoking on disease activity and prognosis of antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study[J]. Pol Arch Intern Med 133(10)","DOI":"10.20452\/pamw.16478"},{"issue":"3","key":"7378_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1378\/chest.13-2388","volume":"146","author":"MJ Strand","year":"2014","unstructured":"Strand MJ, Sprunger D, Cosgrove GP et al (2014) Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia[J]. Chest 146(3):775\u2013785","journal-title":"Chest"},{"issue":"1","key":"7378_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12890-016-0269-2","volume":"16","author":"HM Nurmi","year":"2016","unstructured":"Nurmi HM, Purokivi MK, Karkkainen MS et al (2016) Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes[J]. BMC Pulm Med 16(1):107","journal-title":"BMC Pulm Med"},{"key":"7378_CR21","doi-asserted-by":"publisher","first-page":"406236994","DOI":"10.1177\/1479973121994562","volume":"18","author":"P Zhou","year":"2021","unstructured":"Zhou P, Ma J, Wang G (2021) Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: A systematic literature review and meta-analysis[J]. Chron Respir Dis 18:406236994","journal-title":"Chron Respir Dis"},{"issue":"Suppl 1","key":"7378_CR22","doi-asserted-by":"publisher","first-page":"i83","DOI":"10.1093\/ndt\/gfu385","volume":"30","author":"K Hirayama","year":"2015","unstructured":"Hirayama K, Kobayashi M, Usui J et al (2015) Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan[J]. Nephrol Dial Transplant 30(Suppl 1):i83\u2013i93","journal-title":"Nephrol Dial Transplant"},{"key":"7378_CR23","doi-asserted-by":"publisher","first-page":"1601111168","DOI":"10.1177\/17534666241276800","volume":"18","author":"L Zhai","year":"2024","unstructured":"Zhai L, Wang Z, Yu W (2024) Association between acute exacerbation and progressive pulmonary fibrosis in interstitial lung disease: a retrospective cohort study[J]. Ther Adv Respir Dis 18:1601111168","journal-title":"Ther Adv Respir Dis"},{"key":"7378_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fmed.2017.00176","volume":"4","author":"G Leuschner","year":"2017","unstructured":"Leuschner G, Behr J (2017) Acute Exacerbation in Interstitial Lung Disease[J]. Front Med (Lausanne) 4:176","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"7378_CR25","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/rheumatology\/kead444","volume":"63","author":"S Matsuda","year":"2024","unstructured":"Matsuda S, Kotani T, Okazaki A et al (2024) Prediction model for respiratory-related mortality in microscopic polyangiitis with interstitial lung disease: multicentre REVEAL cohort study[J]. Rheumatology (Oxford) 63(6):1607\u20131615","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"7378_CR26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/resp.14579","volume":"28","author":"TM Maher","year":"2023","unstructured":"Maher TM, Stowasser S, Voss F et al (2023) Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis[J]. Respirology 28(12):1147\u20131153","journal-title":"Respirology"},{"issue":"9","key":"7378_CR27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1513\/AnnalsATS.201606-458OC","volume":"14","author":"MO Paterniti","year":"2017","unstructured":"Paterniti MO, Bi Y, Rekic D et al (2017) Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis[J]. Ann Am Thorac Soc 14(9):1395\u20131402","journal-title":"Ann Am Thorac Soc"},{"issue":"18","key":"7378_CR28","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e120","volume":"36","author":"HC Kwon","year":"2021","unstructured":"Kwon HC, Pyo JY, Lee LE et al (2021) Male Sex Is a Significant Predictor of All-cause Mortality in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis[J]. J Korean Med Sci 36(18):e120","journal-title":"J Korean Med Sci"},{"key":"7378_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m421","volume":"368","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Miloslavsky EM (2020) Management of ANCA associated vasculitis[J]. BMJ 368:m421","journal-title":"BMJ"},{"key":"7378_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2172-15-20","volume":"15","author":"TM Hassan","year":"2014","unstructured":"Hassan TM, Hassan AS, Igoe A et al (2014) Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow - up in ANCA - associated vasculitis[J]. BMC Immunol 15:20","journal-title":"BMC Immunol"},{"issue":"12","key":"7378_CR31","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/rheumatology\/ker266","volume":"50","author":"R Suppiah","year":"2011","unstructured":"Suppiah R, Hadden RD, Batra R et al (2011) Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials[J]. Rheumatology (Oxford) 50(12):2214\u20132222","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"7378_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10067-022-06388-5","volume":"42","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Yamaguchi A, Ito M et al (2023) Clinical differences among patients with myeloperoxidase-antineutrophil cytoplasmic antibody-positive interstitial lung disease[J]. Clin Rheumatol 42(2):479\u2013488","journal-title":"Clin Rheumatol"},{"issue":"1","key":"7378_CR33","doi-asserted-by":"publisher","first-page":"17616","DOI":"10.1038\/s41598-023-45027-0","volume":"13","author":"S Sakamoto","year":"2023","unstructured":"Sakamoto S, Suzuki A, Homma S et al (2023) Outcomes and prognosis of progressive pulmonary fibrosis in patients with antineutrophil cytoplasmic antibody-positive interstitial lung disease[J]. Sci Rep 13(1):17616","journal-title":"Sci Rep"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07378-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T10:54:48Z","timestamp":1744455288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07378-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7378"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07378-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Authors are all agreed to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}